Abstract
Vascular endothelial growth factor (VEGF) plays a major role in the development of aberrant neovascularization in ocular diseases such as diabetic retinopathy and age-related macular degeneration (ARMD), and is an important therapeutic target for these diseases. Monoclonal antibodies specific for VEGF are in clinical use for some patients with ARMD, delivered by intraocular injection. We have shown previously that single chain antibody fragments (scFv) penetrate into the eye when applied topically to the ocular surface. Here we describe the production of a scFv from a monoclonal antibody specific for human VEGF and demonstrate its ability to decrease proliferation of human umbilical vein endothelial cells in culture. A suitably formulated anti-VEGF scFv may have potential as a less invasive topical treatment for potentially blinding neovascular diseases of the eye.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 205-209 |
| Number of pages | 5 |
| Journal | Hybridoma |
| Volume | 28 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 1 2009 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Production of scFv antibody fragments from a hybridoma with functional activity against human vascular endothelial growth factor. / Irani, Yazad; Brereton, Helen M.; Tilton, Ronald; Coster, Douglas J.; Williams, Keryn A.
In: Hybridoma, Vol. 28, No. 3, 01.06.2009, p. 205-209.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Production of scFv antibody fragments from a hybridoma with functional activity against human vascular endothelial growth factor
AU - Irani, Yazad
AU - Brereton, Helen M.
AU - Tilton, Ronald
AU - Coster, Douglas J.
AU - Williams, Keryn A.
PY - 2009/6/1
Y1 - 2009/6/1
N2 - Vascular endothelial growth factor (VEGF) plays a major role in the development of aberrant neovascularization in ocular diseases such as diabetic retinopathy and age-related macular degeneration (ARMD), and is an important therapeutic target for these diseases. Monoclonal antibodies specific for VEGF are in clinical use for some patients with ARMD, delivered by intraocular injection. We have shown previously that single chain antibody fragments (scFv) penetrate into the eye when applied topically to the ocular surface. Here we describe the production of a scFv from a monoclonal antibody specific for human VEGF and demonstrate its ability to decrease proliferation of human umbilical vein endothelial cells in culture. A suitably formulated anti-VEGF scFv may have potential as a less invasive topical treatment for potentially blinding neovascular diseases of the eye.
AB - Vascular endothelial growth factor (VEGF) plays a major role in the development of aberrant neovascularization in ocular diseases such as diabetic retinopathy and age-related macular degeneration (ARMD), and is an important therapeutic target for these diseases. Monoclonal antibodies specific for VEGF are in clinical use for some patients with ARMD, delivered by intraocular injection. We have shown previously that single chain antibody fragments (scFv) penetrate into the eye when applied topically to the ocular surface. Here we describe the production of a scFv from a monoclonal antibody specific for human VEGF and demonstrate its ability to decrease proliferation of human umbilical vein endothelial cells in culture. A suitably formulated anti-VEGF scFv may have potential as a less invasive topical treatment for potentially blinding neovascular diseases of the eye.
UR - http://www.scopus.com/inward/record.url?scp=67651154270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67651154270&partnerID=8YFLogxK
U2 - 10.1089/hyb.2009.0001
DO - 10.1089/hyb.2009.0001
M3 - Article
VL - 28
SP - 205
EP - 209
JO - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
JF - Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
SN - 2167-9436
IS - 3
ER -